{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T14:51:03Z","timestamp":1774018263568,"version":"3.50.1"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The treatment of advanced classical Hodgkin Lymphoma (<jats:styled-content style=\"fixed-case\">cHL<\/jats:styled-content>) has evolved over the last 50\u00a0years with a progressive improvement in long term cure rates in patients up to the age of 60\u00a0years. However, a minority of these survivors experience severe morbidity and mortality resulting from intensive chemotherapy and radiotherapy, leading to a drive to de\u2010escalate treatment without compromising survival. The early identification of patients with chemoresistant disease by functional imaging allows the modulation of therapy and an efficient means to test new agents in those most in need of more effective therapy. The outcomes of treatment for older patients have not improved at the same rate, and this group requires a different approach, incorporating specialist geriatric support to personalise therapy. Clinical trials that focus on quality of life, comorbidity and survival are needed to improve survival rates for this expanding population with complex needs.<\/jats:p>","DOI":"10.1111\/bjh.15622","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T18:24:36Z","timestamp":1541701476000},"page":"60-71","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current treatment paradigms for advanced stage Hodgkin lymphoma"],"prefix":"10.1111","volume":"184","author":[{"given":"Jemma","family":"Longley","sequence":"first","affiliation":[{"name":"Cancer Research UK Centre University of Southampton Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W. M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Cancer Research UK Centre University of Southampton Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022628"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30500-X"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579193"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi023"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3721"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61469-0"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr587"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.110890"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4181"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32134-7"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_80"},{"key":"e_1_2_6_15_1","unstructured":"Cancer Research UK. (2017).Hodgkin lymphoma incidence statistics. Available at:https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/hodgkin-lymphoma\/incidence"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5648"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7503"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-784678"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30696-4"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61940-5"},{"key":"e_1_2_6_24_1","first-page":"0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"79","author":"Evens A.M.","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0910"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6525"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.103218"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_68"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4264"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2151"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0323"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26257"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.0910"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_18"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396556"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.107"},{"key":"e_1_2_6_39_1","first-page":"214507","article-title":"Checkmate 205 cohort D: phase II trial of nivolumab for newly diagnosed advanced stage classical Hodgkin's lymphoma","author":"Ramchandren R.","year":"2018","journal-title":"EHA Learning Center"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4589"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.278"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_53"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4444"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100340"},{"key":"e_1_2_6_46_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V126.23.587.587","article-title":"Brentuximab vedotin in combination with dacarbazine or bendamustine for frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a multi\u2010cohort phase 2 study","volume":"126","author":"Yasenchak C.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70501-1"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13904"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0699"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T12:07:04Z","timestamp":1694606824000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/bjh.15622"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15622","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"2018-11-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}